RESPIRATORY PANEL COMBINED II

Respiratory Panel Combined II is an advanced multiplex molecular diagnostic test designed to simultaneously detect a broad range of respiratory pathogens responsible for upper and lower respiratory tract infections. Using highly sensitive multiplex PCR technology, this panel identifies multiple viruses, bacteria, and atypical respiratory pathogens from a single specimen, allowing rapid and accurate diagnosis.

Respiratory infections often cause symptoms such as fever, cough, sore throat, nasal congestion, wheezing, shortness of breath, chest discomfort, and pneumonia. Because many pathogens produce similar clinical symptoms, laboratory confirmation is essential for identifying the exact cause of infection and guiding appropriate treatment.

Benefits of the Test

• Simultaneously detects multiple respiratory pathogens.
• Provides rapid and highly accurate molecular diagnosis.
• Identifies viral, bacterial, and atypical respiratory infections.
• Supports targeted treatment decisions.
• Reduces unnecessary antibiotic use.
• Helps diagnose pneumonia and severe respiratory illnesses.
• Supports infection control and outbreak monitoring.
• Improves patient outcomes through early detection.

Why Doctors Recommend This Test

Doctors recommend this test for patients with moderate to severe respiratory symptoms, suspected pneumonia, prolonged cough, fever, breathing difficulties, unexplained respiratory illness, recurrent respiratory infections, or hospitalization due to respiratory disease. It is particularly valuable in high-risk populations including children, elderly individuals, immunocompromised patients, and those with chronic lung disease.

The test helps identify the responsible pathogen quickly, allowing healthcare providers to make informed treatment decisions and improve patient management.

Preparation Before Test

• No fasting is required.
• Nasopharyngeal swabs, throat swabs, sputum, or respiratory secretions may be collected.
• Inform your doctor about any recent medications or treatments.
• Follow all instructions provided by healthcare professionals.
• Provide relevant medical history and symptom details.
• Ensure prompt specimen collection and laboratory transport.

Normal Reporting Time

Most Respiratory Panel Combined II reports at Focus Diagnostics are available within 2–3 hours after sample processing. Additional quality verification procedures may occasionally extend reporting time depending on laboratory protocols.

Who Should Take This Test?

This test may be recommended for:

• Patients with acute respiratory tract infections.
• Individuals with suspected viral or bacterial pneumonia.
• People with severe flu-like illness.
• Hospitalized patients with respiratory symptoms.
• Children and elderly individuals.
• Immunocompromised patients.
• Patients with recurrent respiratory infections.
• Individuals requiring comprehensive respiratory pathogen screening.

Detailed Information

Respiratory infections are among the most common infectious diseases worldwide and may range from mild upper respiratory illnesses to severe lower respiratory tract infections and pneumonia. Because clinical symptoms frequently overlap among different pathogens, accurate identification of the causative organism is often difficult without laboratory testing.

Respiratory Panel Combined II utilizes advanced multiplex Polymerase Chain Reaction (PCR) technology to simultaneously detect genetic material from multiple respiratory pathogens. This approach offers superior sensitivity, specificity, and speed compared to conventional culture methods and reduces the need for multiple separate diagnostic tests.

The panel may identify a broad spectrum of respiratory viruses and bacterial pathogens commonly associated with respiratory disease. Depending on the assay configuration, detectable organisms may include Influenza A and B viruses, Respiratory Syncytial Virus (RSV), Adenovirus, Human Metapneumovirus, Rhinovirus, Enterovirus, Parainfluenza viruses, seasonal Coronaviruses, Mycoplasma pneumoniae, Chlamydia pneumoniae, Bordetella pertussis, and other clinically important respiratory pathogens.

Rapid pathogen identification helps distinguish viral infections from bacterial illnesses, allowing clinicians to optimize treatment strategies and reduce inappropriate antibiotic prescribing. Early diagnosis is especially important for patients at increased risk of complications, including infants, elderly individuals, cancer patients, transplant recipients, and those with chronic respiratory disorders.

The test is highly valuable during influenza seasons, community outbreaks, pneumonia investigations, hospital infection control programs, and emergency care settings. Comprehensive respiratory pathogen detection supports evidence-based clinical management and improves overall patient care.

Multiplex respiratory testing also assists in identifying atypical pathogens that may not be detected through routine diagnostic methods. Accurate diagnosis helps clinicians implement appropriate infection prevention measures and monitor disease progression more effectively.

At Focus Diagnostics, Respiratory Panel Combined II testing is performed using state-of-the-art molecular diagnostic platforms, advanced multiplex PCR technology, and stringent quality assurance protocols to provide accurate, reliable, and clinically meaningful diagnostic results.